CAR-T Cell Therapy
in China:
Approved. Accessible.
China has four NMPA-approved CAR-T products — including equivalents to Yescarta and Kymriah — at $60,000–$90,000 versus $400,000–$500,000 in the US. The right product depends on your specific diagnosis: CD19-positive B-cell malignancies, BCMA-positive myeloma, and B-ALL each have different approved options, and clinical trials may outperform approved products for certain presentations. We review your pathology and tell you which route fits your case — then coordinate every step from records transfer to discharge summary.
What Is CAR-T Cell Therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of immunotherapy in which a patient's own T-cells are genetically engineered to recognise and destroy cancer cells. It is considered one of the most significant advances in oncology of the past decade, with durable remission rates in certain blood cancers previously considered untreatable.
Unlike chemotherapy, which attacks all rapidly dividing cells, CAR-T therapy targets a specific protein on cancer cells — most commonly CD19 (found on B-cell malignancies) or BCMA (found on myeloma cells).
Manufacturing takes 7–21 days after leukapheresis (T-cell collection). This is not a same-day procedure. Your treatment timeline will include a bridging therapy period while your cells are being engineered at a GMP-certified facility.
Four Reasons China Has Become a Primary Destination
China is not a workaround. For patients who cannot afford US pricing, or who need access to trials not open elsewhere, it is the primary option.
Which Conditions Can Be Treated?
The distinction between NMPA-approved indications and clinical trial indications matters. Approved indications have established efficacy and safety data. Trial indications are investigational — outcomes are less certain, but access costs are significantly lower.
- Relapsed / Refractory DLBCL2nd line or later
- Follicular Lymphoma3rd line or later (Axi-cel approved)
- Multiple MyelomaBCMA-targeted; relapsed/refractory after 3+ prior lines
- B-Cell Acute Lymphoblastic LeukaemiaPaediatric and adult; relapsed/refractory
- Mantle Cell LymphomaRelapsed/refractory after BTK inhibitor
- Severe Autoimmune DiseaseLupus, myositis, systemic sclerosis — China leads globally
- Solid TumoursLung, liver, gastric, pancreatic — active trials at SYSUCC and Nanfang
- T-Cell LymphomaCD7 and CD5-targeting trials open
- Chronic Lymphocytic Leukaemia (CLL)Phase II trials at multiple centres
- Relapsed DLBCL — 1st Line TrialsExploring CAR-T as frontline treatment
Not sure if you qualify? Send us your latest pathology report and treatment history. We will review your case and advise whether an approved product or clinical trial route is more appropriate — free of charge and within 24 hours. Submit your case →
NMPA-Approved CAR-T Products in China (2026)
These are not generic or counterfeit versions of Western products. They are independently developed and approved, with their own clinical trial data, manufactured at GMP-certified facilities in China.
- Relapsed/Refractory DLBCL (2nd line or later)
- B-Cell Acute Lymphoblastic Leukaemia (paediatric and adult)
- Relapsed/Refractory DLBCL (2nd line or later)
- Follicular Lymphoma (3rd line or later)
- Mantle Cell Lymphoma (after BTK inhibitor)
- Relapsed/Refractory Multiple Myeloma (3+ prior lines)
Indicative estimates for 2026. Final pricing depends on hospital, product availability, and insurance. China Care provides itemised estimates for every case at no charge.
What the Treatment Process Looks Like
From first contact with China Care to discharge summary — a realistic timeline for CAR-T therapy at a Chinese hospital. Plan for a minimum of 4–6 weeks, with 6–8 weeks being more realistic.
Send your pathology report, treatment history, and latest bloodwork via our contact form or WhatsApp. We review your case and recommend approved product versus clinical trial route.
We prepare your hospital invitation letter for the Chinese medical visa application. We coordinate airport transfer, hospital admission, and accommodation near the treatment centre.
On arrival the hospital conducts its own pre-treatment evaluation — bloodwork, bone marrow biopsy if needed, cardiac assessment. This takes 3–5 days and confirms eligibility for the specific product.
T-cells are collected (3–4 hours). Cells ship to the GMP manufacturing facility. Manufacturing takes 7–21 days. During this period you may receive bridging chemotherapy to control disease progression. You cannot leave China during this window.
2–5 days of conditioning chemotherapy, followed by the CAR-T infusion itself (30–60 minutes IV). Most patients are inpatient throughout.
2–4 weeks of inpatient monitoring for CRS and ICANS. Once stable, you return home. We provide a full English discharge summary for your home physician and coordinate any required follow-up imaging.
CAR-T Therapy Cost: China vs. Five Countries
These figures reflect 2024–2026 published and reported costs. The China figures represent approved commercial products — not grey-market or experimental treatments. Canada, Germany, and Singapore costs reflect where the majority of our patients originate.
| Treatment / Indication | 🇺🇸 USA | 🇨🇦 Canada | 🇩🇪 Germany | 🇸🇬 Singapore | 🇧🇷 Brazil | 🇨🇳 China |
|---|---|---|---|---|---|---|
| CD19 CAR-T — Approved Product (DLBCL) | $400K–$450K | CAD 480K–560K | €350K–€420K | SGD 550K–650K | Very limited access | $60K–$80K |
| CD19 CAR-T — Approved Product (FL / MCL) | $400K–$500K | Limited access | €360K–€440K | Limited access | Not available | $65K–$85K |
| BCMA CAR-T — Multiple Myeloma | $420K–$465K | CAD 510K–580K | Not approved | Not approved | Not approved | $70K–$90K |
| CAR-T Clinical Trial (Any indication) | Trial only | Trial only | Trial only | Trial only | Trial only | $15K–$40K |
| CAR-T for Autoimmune Disease | Not approved | Not approved | Not approved | Not approved | Not approved | $40K–$70K |
Costs exclude travel, accommodation, and China Care facilitation fees. Itemised full-cost estimates provided for every patient case at no charge. Request your estimate →
Full Cost Guide →CAR-T Partner Hospitals
Every hospital in our network has been personally evaluated. We have established working relationships with the international patient departments and medical staff at each centre.
From "No Options Left" to Complete Remission
"I had failed two lines of chemotherapy in Canada. My oncologist said CAR-T wasn't available for my subtype. China Care identified a clinical trial at Sun Yat-sen within five days of me sending my records. Fourteen months later, my last PET scan was clear."
Frequently Asked Questions
Is CAR-T therapy in China safe? Are the products the same quality as in the US?
The NMPA-approved products (Relma-cel, Axi-cel, Equecab-cel) are manufactured at GMP-certified facilities under regulatory standards equivalent to FDA GMP requirements. These are not counterfeit or lower-quality versions; they are independently developed and clinically validated products that completed full Phase III trials in China before NMPA approval.
The main risk factor in CAR-T therapy globally is Cytokine Release Syndrome (CRS). Chinese CAR-T centres, particularly high-volume institutions like SYSUCC and Nanfang Hospital, have developed extensive CRS management protocols. In some respects their experience managing complications exceeds many Western centres, simply due to volume.
How long does CAR-T therapy take? How long do I need to stay in China?
Plan for a minimum of 4–6 weeks, with 6–8 weeks being more realistic. The breakdown: hospital assessment (3–5 days), leukapheresis and manufacturing wait (7–21 days), bridging therapy if needed (varies), conditioning chemotherapy (2–5 days), infusion (1 day), post-infusion monitoring (14–28 days).
You cannot leave China during the manufacturing period. The hospital needs to monitor your condition and manage disease with bridging therapy if needed. China Care coordinates hospital-adjacent accommodation for patients and caregivers.
Can I get CAR-T therapy in China if I have already had it elsewhere?
It depends on why you are asking. If you relapsed after a previous CAR-T infusion, you may still be eligible for a second product, especially if the first targeted CD19 and a second targets CD22 or BCMA. This is an active area of clinical research in China.
If you want a second infusion with the same product for the same indication, eligibility is more restricted and depends on your T-cell health and disease status. Submit your case and we will review the options honestly, including telling you if China is not the right next step.
What documents do I need to submit to start the process?
For an initial eligibility assessment: (1) latest pathology report confirming diagnosis and subtype, (2) treatment history including prior lines, drugs received, and response/relapse timeline, (3) most recent blood panel and LDH if available. Full medical records are not needed at this stage.
Once matched to a hospital, they will request a more complete package including imaging reports and bone marrow biopsy results. China Care assists with translation of all documents.
Does China Care get paid by the hospitals? How does your fee work?
China Care charges a fixed facilitation fee directly to the patient. Your treatment cost is quoted directly by the hospital — we never add to it, inflate it, or hide fees inside it. Our recommendation is based on clinical fit for your case. Our fee is the same regardless of which hospital you attend or how expensive your treatment is.
We disclose our fee structure upfront before you commit to anything. There are no hidden charges. The cost estimate we provide includes our fee as a separate line item.
What if the hospital decides I am not eligible after I arrive in China?
This is a real risk and we take it seriously. Before any patient travels, we conduct a pre-screening review of medical records. We will not recommend travel if we believe the hospital is likely to decline. That said, the hospital makes the final eligibility determination on arrival; occasionally a patient's condition changes between submission and arrival.
In those cases, we work with the hospital to identify alternative options: a different product, a clinical trial, or a different treatment modality. We do not leave patients stranded. This is why we remain involved throughout, not just until you arrive.
Can CAR-T therapy in China treat solid tumours?
No CAR-T product, in China or anywhere else, is currently approved for solid tumours. CAR-T for solid tumours is an active area of clinical trial research in China, with trials targeting lung, liver, gastric, and other cancers. Outcomes are less predictable than for haematological malignancies.
If you have a solid tumour, trial participation may be appropriate depending on your cancer's molecular profile. For solid tumour patients we may also recommend considering other advanced therapies available in China such as TCR-T, NK cell therapy, or neoantigen vaccine programmes.
Do I need a medical visa? I am from Canada / Germany / Singapore / Brazil.
Yes, regardless of nationality. International patients seeking inpatient treatment in China require an F-visa (business/medical) or specialised medical visa, supported by an official hospital invitation letter. Treatment duration typically requires a 60-day or 90-day single-entry visa with extension capability.
China Care prepares the hospital invitation letter and guides you through the visa application process. Requirements are similar for Canadian, German, Singaporean, and Brazilian passport holders; processing times vary by embassy. See our complete medical visa guide for 2026 for step-by-step instructions.
Ready to Explore CAR-T Therapy in China?
Send us your diagnosis and treatment history. We will review your case and tell you within 24 hours whether you are a candidate for an approved CAR-T product or a clinical trial — at no cost and no obligation.
